Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 9, 2015-09 ,pp. : 1742-1749

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 70, Iss. 1, 2018-01 ,pp. : 40-48

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 4, 2015-04 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis – an introduction

By Freeman Keith  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 197-203

Informa Healthcare

Access to resources Recommend Favorite

Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland – results of a survey of Scottish health professionals

By Smith Douglas R.W.   Bottomley Julia M.   Auland Merran   Jackson Peter   Sharp Judith  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 239-249

Informa Healthcare

Access to resources Recommend Favorite